Pharmaceutical developer Advanced Magnetics of Cambridge, MA, has signed a research agreement to develop new nucleoside therapeutic drugs with the University of Minnesota in Minneapolis. Under the deal, Advanced Magnetics over the next three years will
Pharmaceutical developer Advanced Magnetics of Cambridge, MA, has signed a research agreement to develop new nucleoside therapeutic drugs with the University of Minnesota in Minneapolis. Under the deal, Advanced Magnetics over the next three years will sponsor research led by Dr. Carston Wagner to develop drug candidates with anti-viral or anti-tumor characteristics. The deal is part of the companys plan to diversify from its core MRI contrast agent market (SCAN 3/18/98).
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.